• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Articles published by Evolus

    < Previous 1 2 Next >
    Evolus to Participate in Stifel 2024 Healthcare Conference
    From Evolus
    Via Business Wire
    Tickers EOLS
    Evolus Announces EU Approval of Estyme® Injectable Hyaluronic Acid Gels Under New Medical Device Regulation
    From Evolus
    Via Business Wire
    Tickers EOLS
    Evolus to Report Third Quarter Financial Results on November 6, 2024
    From Evolus
    Via Business Wire
    Tickers EOLS
    Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Evolus
    Via Business Wire
    Tickers EOLS
    Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Evolus
    Via Business Wire
    Tickers EOLS
    Evolus to Ring the Nasdaq Stock Market Closing Bell on Friday, September 13, 2024
    From Evolus
    Via Business Wire
    Tickers EOLS
    Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Evolus
    Via Business Wire
    Tickers EOLS
    Evolus Reports Second Quarter 2024 Results and Raises Full Year Revenue Guidance
    From Evolus
    Via Business Wire
    Tickers EOLS
    Evolus to Hold Investor Day on September 12, 2024
    From Evolus
    Via Business Wire
    Tickers EOLS
    Evolus to Participate in the Canaccord Genuity 44th Annual Growth Conference
    From Evolus
    Via Business Wire
    Tickers EOLS
    Evolus to Report Second Quarter Financial Results on July 31, 2024
    From Evolus
    Via Business Wire
    Tickers EOLS
    Evolus Announces Appointment of Albert G. White III to Board of Directors
    From Evolus
    Via Business Wire
    Tickers EOLS
    Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for First Two Evolysse™ Dermal Filler Products
    From Evolus
    Via Business Wire
    Tickers EOLS
    Evolus Broadens International Presence with Launch of Nuceiva® (botulinum toxin type A) in Spain
    From Evolus
    Via Business Wire
    Tickers EOLS
    Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Evolus
    Via Business Wire
    Tickers EOLS
    Evolus Announces Positive Data from Pivotal Trial for First Two Evolysse™ Dermal Filler Products at 2024 SCALE Meeting
    From Evolus
    Via Business Wire
    Tickers EOLS
    Evolus Celebrates Fifth Anniversary of Launching its Flagship Product Jeuveau® at the Women’s Wear Daily Beauty CEO Summit
    From Evolus
    Via Business Wire
    Tickers EOLS
    Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Evolus
    Via Business Wire
    Tickers EOLS
    Evolus Reports First Quarter 2024 Results and Provides Business Update
    From Evolus
    Via Business Wire
    Tickers EOLS
    Evolus to Report First Quarter Financial Results on May 7, 2024
    From Evolus
    Via Business Wire
    Tickers EOLS
    Evolus Announces Publication of Safety and Duration Data from Phase 2 Study for “Extra-Strength” 40U Formulation of Jeuveau®
    From Evolus
    Via Business Wire
    Tickers EOLS
    Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Evolus
    Via Business Wire
    Tickers EOLS
    Evolus to Participate in the 23rd Annual Needham Virtual Healthcare Conference
    From Evolus
    Via Business Wire
    Tickers EOLS
    Evolus Announces Pricing of $50.0 Million Underwritten Offering of Common Stock
    From Evolus
    Via Business Wire
    Tickers EOLS
    Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Evolus
    Via Business Wire
    Tickers EOLS
    Evolus Reports Record Fourth Quarter and Full Year 2023 Financial Results; Reaffirms 2024 Guidance
    From Evolus
    Via Business Wire
    Tickers EOLS
    Evolus Announces Results from European Head-to-Head Filler Trial
    From Evolus
    Via Business Wire
    Tickers EOLS
    Evolus to Participate in Upcoming Leerink Partners and Barclays Investor Conferences
    From Evolus
    Via Business Wire
    Tickers EOLS
    Evolus to Report Fourth Quarter and Year End 2023 Results and Provide Business Update on March 7, 2024
    From Evolus
    Via Business Wire
    Tickers EOLS
    Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Evolus
    Via Business Wire
    Tickers EOLS
    < Previous 1 2 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.